precisionbiosciences.com (DTIL) - Price to Earnings Ratio
The Precision BioSciences (DTIL) price chart demonstrates the -7.00 metric, which correlates with successes in in vivo therapy and partnerships with pharma behemoths. The business relies on unique developments for correcting genetic defects, investing massive resources into scientific research. Stability is ensured by retaining leading biochemists through stock options and attracting experts in biopharmaceutical development.
Analytical breakdowns for Precision BioSciences
- market price and analyst price targets:
- market capitalization indicators:
- balance sheet equity data:
- debt and solvency information:
Total Debt to Capital Coefficient Precision BioSciences|DTIL - Long-Term Debt to Equity|Current Liabilities to Capital precisionbiosciences.com|DTIL - Company Debts|Debt to Book Value Ratio Precision BioSciences, Inc.|DTIL - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Precision BioSciences|Quick Liquidity precisionbiosciences.com
- earnings and market multiples details:
DTIL - Net Profit|Company Profit Forecast Precision BioSciences|DTIL - Price to Earnings Ratio|Projected Price to Earnings Ratio Precision BioSciences Inc.|DTIL - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Precision BioSciences, Inc.|DTIL - Operating profit EBITDA|Net earnings per share for the last 12 months Precision BioSciences|DTIL - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months precisionbiosciences.com|DTIL - Earnings growth in current year|Expected net earnings per share growth next year Precision BioSciences
Comprehensive company analysis:Precision BioSciences Inc. DTIL
The P/E ratio reflects the market value of a share relative to past earnings, demonstrating the extent to which an asset's price is overvalued or undervalued depending on interest rates. By analyzing the P/E history of Precision BioSciences (DTIL), an investor assesses the stability of the company's capitalization, where high borrowing costs could negatively impact expenses for the high-tech transport of bioreactors and genome editing reagents.
Competing companies
Market Cap to Earnings Tempus AI Inc TEM|P/E Multiple QGEN|Price to Earnings Ratio Ionis Pharmaceuticals, Inc. IONS|P/E Multiple RGEN (Repligen Corp.)|Business Payback Period Avidity Corp (RNA)|CRSP - Price to Earnings Ratio|Business Payback Period genedx.com WGS|RARE: P/E Multiple|BEAM - Business Payback Period|Price to Earnings Ratio Sarepta Therapeutics Inc|Market Cap to Earnings Twist Bioscience Corp TWST|Price to Earnings Ratio 10x Genomics, Inc. (TXG)|intelliatx.com - Price to Earnings Multiple|Stoke Therapeutics, Inc. - Price to Earnings Ratio|Company Value to Net Income BLFS|Wave Life Sciences Corp - P/E Multiple|MAZE: Price to Earnings Ratio|SION: P/E Multiple|PRME - Business Payback Period|Price to Earnings Ratio Taysha Gene Therapies, Inc.|Market Cap to Earnings uniQure NV QURE|Price to Earnings Ratio MeiraGTx PLC (MGTX)|Business Payback Period REGENXBIO Corp|P/E Multiple SLDB (Solid Biosciences Inc.)|OCGN - Price to Earnings Ratio|PacBio - P/E Multiple|Business Payback Period Benitec Biopharma Inc BNTC|DSGN: P/E Multiple|Market Cap to Earnings Rocket Corp (RCKT)|Price to Earnings Ratio 4D Molecular Therapeutics|Price to Earnings Multiple LXEO (Lexeo)|P/E Multiple KRRO|Price to Earnings Ratio Editas Medicine Inc EDIT|P/E Multiple SLN (Silence Therapeutics Inc.)|ProQR (PRQR) - Market Cap to Earnings|CDXS - Price to Earnings Ratio|Business Payback Period sangamo.com SGMO|NAUT: P/E Multiple|Price to Earnings Multiple MGX|Price to Earnings Ratio GBIO|BOLD (Boundless Bio Inc) - Market Price to Net Income Ratio|P/E Multiple XCUR|Business Payback Period imunon.com|Price to Earnings Ratio Phio Pharmaceuticals Corp. PHIO|Mustang Bio Inc - Price to Earnings Ratio|TransCode - P/E Multiple|BNGO (Bionano Genomics, Inc.) - Price to Earnings Multiple|Applied DNA Sciences (APDN) - Price to Earnings Ratio|Price to Earnings Multiple BLUE|IPA (ImmunoPrecise Antibodies Ltd) - P/E Multiple|P/E Multiple Omega Therapeutics Inc|Price to Earnings Ratio Singular Genomics Systems Inc (OMIC)|RGLS: Market Cap to Net Income|Price to Earnings Ratio Syros Pharmaceuticals SYRS|Company Value to Net Income TBIO|TRACON Pharmaceuticals, Inc. - P/E Multiple|Market Cap to Earnings Unity Biotechnology Inc.
